Name | Ciraparantag TFA |
---|
Description | Ciraparantag TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban[1][2][3][4]. |
---|---|
Related Catalog | |
Target |
thrombin, factor Xa[1] |
In Vitro | Ciraparantag TFA is a small-molecule antidote for unfractionated heparin (UFH), low-molecular-weight heparin (LMWH), and certain direct oral anticoagulants (DOACs)[2]. Ciraparantag TFA is a small synthetic and cationic molecule that binds direct Xa inhibitors, direct thrombin inhibitors, and unfractionated and low molecular weight heparin (LMWH) through non-covalent hydrogen bonds and charge–charge interactions[3]. |
References |
Molecular Formula | C26H50F6N12O6 |
---|---|
Molecular Weight | 740.74 |